Cartesian Therapeutics (RNAC) announced the granting of inducement awards to three new employees. On June 2, 2025, the Company issued to these employees options to purchase an aggregate of 26,350 shares of the Company’s common stock with an exercise price of $9.98, the closing trading price of the Company’s common stock on the Nasdaq Global Market on the date of grant. The options were granted pursuant to the Company’s Amended and Restated 2018 Employment Inducement Incentive Award Plan and were approved by the Company’s board of directors. The options vest as to 25% on June 2, 2026, and then in three equal annual installments thereafter such that the options will be fully vested on June 2, 2029. The options have a ten-year term. The options were granted under Rule 5635(c)(4) of the Nasdaq Listing Rules as an inducement material to the employees’ entry into employment with the Company.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RNAC:
- Promising Outlook for Cartesian Therapeutics: Buy Rating Backed by Advancements in Descartes-08 Trials and Strong Financial Projections
- Cartesian announces first participant enrolled in Phase 3 AURORA trial
- Cartesian selloff brings ‘attractive buying opportunity,’ says Mizuho
- Optimistic Buy Rating for Cartesian Therapeutics Driven by Promising mRNA-Based CAR-T Developments and Strategic Clinical Advancements
- Promising Potential of Cartesian Therapeutics’ Descartes-08 Therapy Drives Buy Rating